United States Patent 5,997,899: Claim Scope, Expiration, and Multivesicular Liposome Patent Landscape

U.S. Patent No. 5,997,899 protects a formulation-screening method for increasing the encapsulation efficiency of multivesicular liposomes. Its central requirement is replacing a shorter-chain amphipathic lipid with a chemically similar lipid having longer fatty-acyl chains and demonstrating increased encapsulation.

The patent does not broadly claim every multivesicular liposome, every liposome containing a therapeutic compound, or the longer-chain lipid compositions themselves. Its enforceable scope, while the patent was in force, depended on performance of the claimed substitution-and-measurement method.

What does U.S. Patent 5,997,899 claim?

The independent claim requires five operative elements:

Element	Claim requirement
Liposome type	A multivesicular liposome
Initial formulation	At least one encapsulated compound and a first amphipathic lipid having a carbon chain of approximately 1 to 12 carbons
Measurement	Determining the percentage of compound encapsulated
Substitution	Replacing the first lipid with a chemically similar second amphipathic lipid
Chain-length change	The second lipid has 1 to 16 additional carbons in a fatty-acyl chain
Result	The longer chain increases the percentage of compound encapsulated

The claim is a method claim. It requires a sequence of formulation operations and a measured result. A liposome product that happens to contain a longer-chain lipid is not automatically within claim 1 unless the claimed method is practiced.

The patent is directed to multivesicular liposomes, commonly associated with the DepoFoam delivery platform. Multivesicular liposomes contain multiple nonconcentric aqueous chambers separated by lipid membranes. Their encapsulation performance depends on lipid composition, lipid-chain length, charge, saturation, solvent conditions, drug properties and manufacturing conditions.

How broad is claim 1 of U.S. Patent 5,997,899?

Claim 1 has technically broad language but several limiting conditions.

Broad technical features

The claim permits:

Any conventional method for forming the multivesicular liposome.
Any encapsulated compound.
Any amphipathic lipid with an initial chain length of approximately 1 to 12 carbons.
A second lipid with a substantially similar chemical structure.
An increase of 1 to 16 carbons in a fatty-acyl chain.
More than one possible lipid substitution.

The phrase "by any conventional means" avoids limiting the claim to one manufacturing process. A competitor could therefore face claim exposure even if it uses a different solvent system, mixing method, loading process or equipment configuration, provided the other claim elements are met.

Limiting technical features

The claim does not cover every change in lipid chain length. The second lipid must have a substantially similar chemical structure. A substitution involving a different lipid class, headgroup, charge or backbone may fall outside the claim if the structural difference is material.

The claim also requires the increased chain length to produce an increase in encapsulation. A formulation change that uses a longer-chain lipid but does not increase encapsulation would not satisfy the result limitation.

The claim requires a determination of encapsulation percentage. A formulation developer that performs the substitution without measuring or determining encapsulation may present a dispute over whether the method was practiced, although internal analytical data, development records and batch-release testing could establish the required step.

What dependent claims add to the patent scope

The dependent claims narrow the general method into performance ranges, lipid classes and chain-length changes.

Claims	Added limitation	Practical effect
2	Encapsulation increased to approximately 7.5% to 50%	Covers a lower efficiency range
3	Initial chain length of 12 or fewer carbons changed to approximately 13 to 22 carbons	Defines the principal short-chain to longer-chain transition
4	Amphipathic lipid is a phospholipid	Excludes non-phospholipid embodiments
5	Phospholipid is saturated	Narrows the lipid chemistry
6	Encapsulation increased to approximately 30% to 85%	Covers a higher efficiency range
7	Specific phosphatidylcholine and phosphatidylglycerol species	Creates species-level fallback positions
8-10	Specific initial chain lengths and minimum increases	Attempts to target selected chain-length transitions
11-12	Increase of four, six or more carbons	Covers larger chain-length substitutions
13-16	Increase in the SN1 chain, SN2 chain or both	Addresses positional changes in glycerol-linked acyl chains
17	Steps performed only until desired efficiency is determined	Limits repeated screening activity
18	Only substitution step performed after formulation is determined	Targets production or later implementation
19	Two or more initial lipids are substituted	Covers multi-lipid formulation optimization
20	Two or more compounds are encapsulated	Covers combination payloads

Claims 4 through 7 are commercially important because they focus on phospholipids used in multivesicular liposome formulations. Claims 13 through 16 attempt to prevent design-around through selective modification of one acyl position rather than both.

What formulations are protected by U.S. Patent 5,997,899?

The listed lipid species include phosphatidylcholines and phosphatidylglycerols with saturated or unsaturated acyl chains. The claim text identifies compounds including:

1,2-dilauroyl-sn-glycero-3-phosphocholine
1,2-dimyristoyl-sn-glycero-3-phosphocholine
1,2-dipalmitoyl-sn-glycero-3-phosphocholine
1,2-distearoyl-sn-glycero-3-phosphocholine
1,2-diarachidoyl-sn-glycero-3-phosphocholine
1,2-dibehenoyl-sn-glycero-3-phosphocholine
1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol
1,2-dioleoyl-sn-glycero-3-phosphoglycerol

The commercial significance is the relationship between acyl-chain length and encapsulation efficiency. The claims seek to protect formulation optimization as a repeatable development technique rather than a single finished dosage form.

The patent does not expressly require a particular drug, route of administration, dosage strength, particle size, release profile or therapeutic indication. Claim 20 extends the concept to formulations containing at least two encapsulated compounds.

Are claims 8, 9 and 10 internally consistent?

Claims 8, 9 and 10 present a material drafting issue. Each depends on claim 1 but states that the first lipid contains 14, 16 or 18 carbons. Claim 1 requires the first amphipathic lipid to have a carbon chain of approximately 1 to 12 carbons.

This creates a facial inconsistency:

Claim 8: first chain contains 14 carbons.
Claim 9: first chain contains 16 carbons.
Claim 10: first chain contains 18 carbons.
Claim 1: first chain contains no more than approximately 12 carbons.

A dependent claim ordinarily incorporates every limitation of the claim from which it depends. The claims may have been intended to refer to a different claim branch, or to describe a separate experimental embodiment. As written, claims 8 through 10 create vulnerability to an indefiniteness or claim-construction challenge. A court could attempt to reconcile the claims with the specification, but it would not be appropriate to assume that the numerical conflict is harmless.

Claims 7 and 13 also contain drafting defects, including duplicated lipid language and nomenclature errors. Those defects may affect construction of the species-level limitations but do not necessarily eliminate the scope of claim 1.

When did U.S. Patent 5,997,899 lose exclusivity?

U.S. Patent 5,997,899 is an issued utility patent from 1999. Its ordinary patent term was governed by the 20-year term measured from the applicable nonprovisional filing date, subject to any patent-term adjustment or other statutory extension. A patent issued in 1999 with a conventional 1997 filing chronology would ordinarily expire in 2017, absent an unusual term adjustment.

The patent is therefore no longer a live U.S. barrier to generic or competitive formulation development. It cannot presently support an ordinary patent-infringement claim for conduct occurring after expiration. The exact terminal disclaimer, patent-term adjustment and maintenance-fee history should be read from the USPTO Patent Center record before relying on a day-specific expiration date. The operative commercial conclusion is that the patent’s ordinary term has ended.

Event	Timing
Application filing	Before the 1999 grant; the term is measured from the applicable nonprovisional filing date
Patent issuance	1999
Ordinary 20-year term	Approximately 2017-2019, depending on the effective filing date and adjustment
Current status	Expired by the ordinary statutory term

Patent expiration does not erase the historical relevance of the patent. It can remain relevant to freedom-to-operate analyses involving earlier products, damages periods, prosecution history and the interpretation of related patent families.

What is the Orange Book status of U.S. Patent 5,997,899?

U.S. Patent 5,997,899 is not, by its claim format, an Orange Book product patent. It claims a liposome formulation method and does not identify a specific approved drug product, active ingredient, dosage form or approved use.

Orange Book listing is tied to patents submitted for approved drug products under the FDA’s regulatory framework. A formulation-development patent may be commercially important without appearing in the Orange Book. Its absence would not establish that no other patents cover a product.

For an approved liposomal drug, relevant patent categories can include:

Drug substance patents.
Lipid composition patents.
Liposome structure or particle-size patents.
Manufacturing-process patents.
Release-profile patents.
Method-of-use patents.
Device or administration patents.

Patent 5,997,899 falls primarily within the formulation and manufacturing-method category.

Did the patent create Paragraph IV or generic-entry risk?

The patent could have created Paragraph IV risk while active if it was listed against an approved drug and if a generic applicant’s development process practiced the claimed method. The claim itself, however, would not automatically block all abbreviated new drug applications for liposomal products.

A Paragraph IV challenge would have required a listed patent, a relevant approved product, and a certification that the patent was invalid, unenforceable or would not be infringed. For a method-of-manufacture claim, infringement analysis would focus on the process used to make the proposed product.

Because the patent has expired, it does not currently create a Paragraph IV launch barrier. Current entry risk would instead arise from later-expiring patents covering the specific liposomal product, its formulation, manufacturing process or approved use.

How strong was the patent estate?

Strengths

The patent had several meaningful strengths during its term:

Claim 1 was not tied to one drug or one commercial product.
The claim covered formulation optimization across multiple lipid classes.
The required result, increased encapsulation, could be demonstrated experimentally.
The specification presumably supported a relationship between longer acyl chains and higher loading efficiency.
Claims 17 through 20 attempted to capture both development-stage screening and later production implementation.

Weaknesses

The principal weaknesses were:

The "substantially similar chemical structure" limitation is open to interpretation.
"About" and "approximately" create numerical claim-construction issues.
The claim requires proof that the substitution caused an increase.
The scope of "determining" encapsulation percentage may be disputed.
Claims 8 through 10 conflict with the 1-to-12-carbon limitation in claim 1.
The listed lipid nomenclature contains apparent typographical errors.
A competitor could avoid the method by changing lipid headgroups, using a different formulation strategy or relying on a process that does not perform the claimed substitution.

The patent was stronger against a company that deliberately screened short-chain lipids and then substituted homologous longer-chain phospholipids. It was weaker against a company that selected a final composition directly, used a materially different lipid structure or relied on a different encapsulation mechanism.

What manufacturing and intellectual-property barriers remain?

The expired patent removes one historical barrier, but multivesicular liposome products remain technically difficult to develop. Current barriers can include:

Reproducible formation of multiple internal aqueous chambers.
Control of particle-size distribution.
Prevention of leakage during storage.
Sterility and aseptic processing.
Control of residual organic solvents.
Consistent drug loading.
Release-rate reproducibility.
Scale-up from laboratory mixing to commercial equipment.
Stability of lipid components and encapsulated compounds.
Container-closure compatibility.
Analytical methods for free versus encapsulated drug.

These technical barriers can support later patents even when the broad lipid-chain optimization concept is no longer enforceable. A current competitor must review the active patent families of the product sponsor, not only historical multivesicular-liposome patents.

What litigation, licensing and settlement issues affect the patent?

The claim text itself does not establish a litigation history, licensing agreement or settlement. Patent 5,997,899 should not be treated as evidence of a current dispute or license obligation.

The commercial value of the patent historically would have depended on its relationship to multivesicular-liposome platform rights and any drug-specific agreements. A license to a broader delivery platform would not necessarily prove that this patent remains enforceable. Conversely, expiration of this patent would not terminate separate licenses covering active patents, know-how, trademarks or manufacturing technology.

No current generic-entry restriction should be attributed to this patent alone.

How does this patent compare with product-specific liposome patents?

Attribute	U.S. 5,997,899	Product-specific liposome patent
Claim type	Formulation-development method	Composition, product, use or manufacturing claim
Required drug	None specified	Usually specified or structurally defined
Required lipid	Broad class, with chain-length change	Often defined lipid ratios or species
Infringement focus	Conduct and formulation-development steps	Product characteristics or manufacturing process
Design-around path	Change lipid structure or optimization method	Alter composition, process, dose or use
Orange Book relevance	Generally indirect	Potentially direct if listed for an approved product
Current term	Expired by ordinary term	Depends on each later patent family

Key Takeaways

U.S. Patent 5,997,899 claims a method for increasing multivesicular-liposome encapsulation by replacing short-chain amphipathic lipids with structurally similar longer-chain lipids.
The patent does not broadly claim all multivesicular liposomes or all formulations containing longer-chain phospholipids.
Claim 1 requires formation, measurement, substitution and a demonstrated increase in encapsulation.
Claims 4 through 7 focus the invention on phospholipid and specific lipid-species embodiments.
Claims 8 through 10 contain a material inconsistency because they recite initial chains longer than the 1-to-12-carbon range incorporated from claim 1.
The patent’s ordinary U.S. term ended years ago, so it is not a current standalone generic-entry barrier.
Orange Book relevance cannot be inferred from this formulation-method patent and is generally indirect.
Current freedom-to-operate risk must be assessed against later-expiring product, formulation, manufacturing and method-of-use patents.
The patent’s historical strength was greatest against direct use of homologous longer-chain lipid substitutions during liposome formulation development.

FAQs About U.S. Patent 5,997,899

Can a company sell a liposome product containing a longer-chain phospholipid?

Yes, this expired patent does not presently prohibit sale based solely on the lipid-chain composition. Earlier infringement exposure would have depended on whether the company practiced the claimed method while the patent was in force.

Does the patent cover doxorubicin liposomes?

No specific drug is required by claim 1. A doxorubicin liposome could have implicated the patent only if its development or manufacture satisfied every limitation of an unexpired claim.

Is this patent a composition-of-matter patent?

No. It is principally a method patent directed to improving encapsulation efficiency through lipid substitution.

Can a competitor avoid the patent by changing the phospholipid headgroup?

While the patent was active, a material headgroup change could have supported a noninfringement position because claim 1 requires the second lipid to have a substantially similar chemical structure. The result would have depended on claim construction and the technical facts.

Does patent expiration eliminate all multivesicular-liposome patent risk?

No. Expiration eliminates the enforceability of this patent, not later patents covering a specific drug, lipid ratio, release profile, manufacturing process, indication or delivery system.

References

United States Patent and Trademark Office. (1999). Methods for increasing the encapsulation efficiency of multivesicular liposomes, U.S. Patent No. 5,997,899.
United States Patent and Trademark Office. (n.d.). Manual of Patent Examining Procedure, Chapter 2700: Patent term and adjustment. U.S. Department of Commerce.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	4657997	⤷ Start Trial
Australia	738020	⤷ Start Trial
Canada	2267416	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,997,899

Summary for Patent: 5,997,899